Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLA1 | P09884 | 4/20 | 0.68 |
| ▸ | NR1H2 | P55055 | 11/20 | 0.68 |
| ▸ | NR1H3 | Q13133 | 11/20 | 0.68 |
| ▸ | KARS1 | Q15046 | 2/20 | 0.67 |
| ▸ | RXRA | P19793 | 1/20 | 0.67 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.67 |
| ▸ | CDK2 | P24941 | 1/20 | 0.67 |
| ▸ | RXRB | P28702 | 1/20 | 0.67 |
| ▸ | RXRG | P48443 | 1/20 | 0.67 |
| ▸ | POLB | P06746 | 1/20 | 0.65 |
| ▸ | APEX1 | P27695 | 1/20 | 0.65 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31181392 | 1.00 | POLA1 (0.68) | POLA1NR1H2NR1H3KARS1RXRA | |
| SCHEMBL2985198 | 0.88 | LMNA (0.67) | POLA1NR1H2NR1H3KARS1RXRA | |
| SCHEMBL6391596 | 0.88 | LMNA (0.67) | POLA1NR1H2NR1H3KARS1RXRA | |
| SCHEMBL15339315 | 0.86 | SOD1 (0.73) | POLA1NR1H2NR1H3 | |
| SCHEMBL3286836 | 0.85 | POLA1 (0.54) | POLA1NR1H2NR1H3KARS1RXRA | |
| Podocaric Acid SCHEMBL32474685 | 0.84 | NR1H2 (0.80) | POLA1NR1H2NR1H3KARS1RXRA | |
| Podocaric Acid SCHEMBL14389445 | 0.84 | NR1H2 (0.80) | POLA1NR1H2NR1H3KARS1RXRA | |
| Podocaric Acid SCHEMBL6311820 | 0.84 | NR1H2 (0.80) | POLA1NR1H2NR1H3KARS1RXRA | |
| Podocaric Acid SCHEMBL31181390 | 0.84 | NR1H2 (0.80) | POLA1NR1H2NR1H3KARS1RXRA | |
| Podocaric Acid SCHEMBL160062 | 0.84 | NR1H2 (0.80) | POLA1NR1H2NR1H3KARS1RXRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180193294-A1 | Dehydroabietic acid (DHAA) derivatives for use as ion channel openers | ELINDER FREDRIK (SE) | 2018-07-12 | — | — | US | claimed |
| US-20180193294-A1 | Dehydroabietic acid (DHAA) derivatives for use as ion channel openers | ELINDER FREDRIK (SE) | 2018-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180193294-A1 | Dehydroabietic acid (DHAA) derivatives for use as ion channel openers | KCNAB1, KCNA1, KCNE1 | POLA1 2181/4885NR1H2 1523/4885NR1H3 1578/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.